Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Meina T. Tang"'
Autor:
Nastya Kassir, Rui Zhu, Anita Moein, Jurgen Langenhorst, Jakob Ribbing, Rong Zhang, Meina T. Tang, Young S. Oh, Wenhui Zhang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 9, Pp 1234-1243 (2022)
Abstract Etrolizumab is an IgG1‐humanized monoclonal anti‐β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately‐to‐severely active ulcerative colitis (UC) who were either p
Externí odkaz:
https://doaj.org/article/8678c1be491e4d60aa7f5d8efa301631
Autor:
Rui Zhu, Angelica Quartino, Matts Kågedal, Wenhui Zhang, Meina T. Tang, Tong Lu, Sonoko Kawakatsu
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 49:179-190
Clinical trials in patients with ulcerative colitis (UC) face the challenge of high and variable placebo response rates. The Mayo Clinical Score (MCS) is used widely as the primary endpoint in clinical trials to describe the clinical status of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d20fde35d0bec463dc5d0bb2847b17
https://doi.org/10.1007/s10928-021-09789-2
https://doi.org/10.1007/s10928-021-09789-2
Autor:
Sharon O'Byrne, Leonid Gibiansky, Yehong Wang, Xiaohui Wei, Franklin Fuh, Rich Erickson, Meina T. Tang
Publikováno v:
Journal of Clinical Pharmacology
Etrolizumab, a humanized monoclonal antibody, specifically binds to the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. Pharmacokinetic (PK) and pharmacodynamic (PD) data were collected from an etrolizumab phase 1 trial in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d4af8790d77063fcec4dd624bda2b4
http://europepmc.org/articles/PMC5836964
http://europepmc.org/articles/PMC5836964
Autor:
Rong Deng, C. Andrew Boswell, Wendy S. Putnam, Meina T. Tang, Amit Garg, Chunze Li, Shan Chung, Sandhya Girish
Publikováno v:
Pharmaceutical Biotechnology ISBN: 9783030007096
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::234b57b005b6776be94a3472c31da73f
https://doi.org/10.1007/978-3-030-00710-2_8
https://doi.org/10.1007/978-3-030-00710-2_8
Autor:
Jane R. Kenny, Meina T. Tang, Xiaohui Wei, Romeo Maciuca, Leslie J. Dickmann, Caroline Looney
Publikováno v:
Journal of Clinical Pharmacology
The efficacy and safety of etrolizumab, a humanized IgG1 mAb, were evaluated in patients with ulcerative colitis (UC) in a phase 2 study (EUCALYPTUS). The current study assessed the risk of therapeutic protein drug‐drug interaction (TP‐DDI) of et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e013695bef265ae6e3179cb70fcb00d0
http://europepmc.org/articles/PMC5066705
http://europepmc.org/articles/PMC5066705
Publikováno v:
Clinical Pharmacokinetics. 53:907-918
Daclizumab is a humanized monoclonal antibody that blocks the α-subunit of the interleukin-2 receptor with demonstrated benefits in the treatment of multiple sclerosis. The present work aimed to characterize the pharmacokinetics of daclizumab high-y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2361803f3d4c6db5266a0e11d6a7b15d
https://doi.org/10.1007/s40262-014-0159-9
https://doi.org/10.1007/s40262-014-0159-9
Autor:
Wenhui Zhang, Julián Panés, Rhian Jacob, Franklin Fuh, William J. Sandborn, Rich Erickson, Jacqueline McBride, Meina T. Tang
Publikováno v:
Inflammatory Bowel Diseases. 25:S17-S17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b1759a819afe12ad05892626b9780a
https://doi.org/10.1093/ibd/izy393.040
https://doi.org/10.1093/ibd/izy393.040
Autor:
Jia Shi, Jeffrey Harris, Katherine Riester, Ying Zhang, Lyubov Efros, Vladimir Vexler, Jacob Elkins, Meina T Tang, James Sheridan
Publikováno v:
Multiple Sclerosis Journal. 17:1441-1448
Objective: The objective of this study was to evaluate whether interleukin-2 (IL-2) receptor expression on CD56bright natural killer (NK) cells predicted CD56bright NK cell expansion and therapeutic response to daclizumab (DAC) in multiple sclerosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510c7feabefd172422e8e352b97dd85c
https://doi.org/10.1177/1352458511414755
https://doi.org/10.1177/1352458511414755
Autor:
Ann Herman, Priscilla Horn, John C. Davis, Meina T. Tang, Carolyn Offutt, J Abraham Simon, Frank Hsieh, Michael J. Townsend, William P Kennedy, Jane L. Grogan
Publikováno v:
Arthritis Research & Therapy
Tumor necrosis factor (TNF) and, possibly, lymphotoxin alpha (LTα) signaling contribute to inflammation and rheumatoid arthritis (RA) pathogenesis. Pateclizumab (anti-lymphotoxin- alpha; MLTA3698A) is a humanized monoclonal antibody that blocks and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::947ffd273ae90d5e921d8d4e9544d5db
https://doi.org/10.1186/s13075-014-0467-3
https://doi.org/10.1186/s13075-014-0467-3
Autor:
Ago B. Ahene, Jihong Yang, Hossein Salimi-Moosavi, Meina T. Tang, Jian-Feng Lu, John Kamerud, Heather Myler, Lindsay King, Jean W. Lee, Marian Kelley, Cindy Rogers
The predominant driver of bioanalysis in supporting drug development is the intended use of the data. Ligand-binding assays (LBA) are widely used for the analysis of protein biotherapeutics and target ligands (L) to support pharmacokinetics/pharmacod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47f191a6fd5477b5ab928a2fd24a6743
https://europepmc.org/articles/PMC3032085/
https://europepmc.org/articles/PMC3032085/